
285 participants aged 12-17 will test Lundbeck's drug Vyepti as a preventative treatment for migraines over the next year.
This was revealed when Lundbeck registered the study at clinicaltrials.org, a publicly run database of trials of approved medicines.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app